Opiant Pharmaceuticals, Inc.

NasdaqCM:OPNT Stok Raporu

Piyasa değeri: US$108.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Opiant Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Opiant Pharmaceuticals şirketinin kazançları yıllık ortalama -22.2% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 0.4% oranında azalan oldu. Gelirler yıllık ortalama 10.3% oranında artan oldu.

Anahtar bilgiler

-22.2%

Kazanç büyüme oranı

-10.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı10.3%
Özkaynak getirisi-161.4%
Net Marj-148.1%
Son Kazanç Güncellemesi30 Sep 2022

Yakın geçmiş performans güncellemeleri

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21
Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19
Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17
These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09
Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06
The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05
News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27
Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

Gelir ve Gider Dağılımı

Opiant Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:OPNT Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 2222-33240
30 Jun 2239-20230
31 Mar 2246-6200
31 Dec 21483170
30 Sep 21442160
30 Jun 2137-1160
31 Mar 2132-3160
31 Dec 2030-2160
30 Sep 20270150
30 Jun 203910150
31 Mar 203912130
31 Dec 194112130
30 Sep 19381120
30 Jun 1921-11120
31 Mar 1918-14120
31 Dec 1814-21110
30 Sep 1834-2180
30 Jun 1829-5170
31 Mar 1830-3160
31 Dec 17283150
31 Oct 17172114
31 Jul 1718780
30 Apr 1715672
31 Jan 1718953
31 Oct 1611353
31 Jul 1610-8153
30 Apr 1610-8154

Kaliteli Kazançlar: OPNT şu anda kârlı değil.

Büyüyen Kar Marjı: OPNT şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: OPNT kârlı değildir ve zararlar son 5 yılda yılda 22.2% oranında artmıştır.

Büyüme Hızlandırma: OPNT 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: OPNT kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 9.5% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: OPNT hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -161.39% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin